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Introduction
The two articles in this month’s press of The Journal of Arthritis, one
by Ekinci et al. titled ‘A New Treatment Option in Osteoarthritis:
Prolotherapy Injections’ and the other by Senatorov et al. titled
‘Clinical Outcome of Hylan G-F 20 Injections in Shoulder and Hip
Osteoarthritis: A Retrospective Review’ raise several important points
surrounding the topic of intra-articular injections [1,2]. Firstly that
there is a paucity of high quality literature in the field that often leads
to inconclusive or misrepresented conclusions on drug efficacy in
established treatments [1,2]. The articles also highlight the
heterogeneity in injection procedure, site, concentration, preparation
and outcome measurements [1,2]. This editorial will, therefore, provide
a concise review on some of the current injection therapies and suggest
possible improvements to methodological structure to inspire readers
strive for high quality data. Further, through an example of a possible
novel therapy, Actovegin, this editorial will hopefully challenge readers’
way of thinking to consider the reapplication of established drugs;
posing the question can you teach an old drug new tricks?
Cochrane review of 27 randomised control trials examining the
effect of cortical steroid injections in Osteoarthritis reported an
improved response to pain and function with cortical steroid treated
patients when compared to placebo in smaller trials of low
methodological quality and power with selected subgroups of patients
[3]. On the other hand larger trials with more rigorous selection
criteria demonstrated limited effect of cortical steroid at 6 weeks,
questioning its efficacy [3]. Interestingly the Cochrane Musculoskeletal
Group 2015 would consider cortical steroid to still be experimental in
treating knee OA, they highlight two key issues for injection therapy.
The need of well-constructed, blinded, sham intervention/placebo
controlled with adequately randomised and powered trials in
established therapies [3]. Obviously in a clinical setting this is not
always possible, yet for upcoming therapies there is a need to strive for
this gold standard of research.
The effect in meta-analyses caused by the wide variety of
preparations and dosage [3]. Should preparations such as
Betamethasone, Dexamethasone, Prednisolone and Triamcinolone be
evaluated under the same cortical steroid review? Certainly their
efficacy should be assessed and considered individually and a dose
response relationship calculated if any at all. Furthermore, most
clinicians would mix a cortical steroid with different types of
anaesthetic agents prior to injection; therefore their
pharmacodynamics and pharmacokinetic property cannot be
predicted.
Another popular substance used for injection therapy is Platelet
Rich Plasma (PRP); the literature on PRP injections raises similar
points. Of the 11 studies included in a Review by Simental-Mendíaa et
al. across the board, all demonstrated safety and improvements in pain
and function scores [4]. Further, in most cases when compared to
Hyaluronic Acid (HA) preparations PRP showed superior
improvements in pain and functional improvement in the treatment of
OA [4]. Again studies included were generally case series of an
unblinded or uncontrolled nature [4]. The point to highlight here again
is that, PRP is highly dependent on the quality of patient’s own blood
growth factor concentrations and therefore no standardisation exists
for randomised control trialling. Due to the large variation in patient
global health and comorbidities, is it really possible to compare results
of PRP use in OA?
Prolotherapy, as comprehensively covered by Ekinci et al. in this
issue, is a combination of hypertonic dextrose, erythropoietin and local
anaesthetic solutions [1]. Dextrose solutions above 10% act by
inducing osmotic rupture of local cells and increase growth factors in
the extracellular matrix [1]. This concise review article advocates the
safe use of Prolotherapy injections and echoes our thoughts on the
limitations of current literature by low power, poor quality study and
variation in drug preparations [1]. Ekinci et al. fittingly suggest that
future high quality research should elucidate the ideal strategy for
Prolotherapy injection [1].
Intra-articular injection of HA as advocated through a retrospective
case review by Senatorov et al. in this issue, here demonstrates the
importance of case series data as a guide for future prospective clinical
trials that could validate their conclusions [2]. The retrospective review
of 26 subjects undergoing Hylan G-F 20 eloquently demonstrated
safety and efficacy; adding clinical evidence to the hypothesis that HA
can be effective in patients with end stage osteoarthritis [2].
Further research could review the effects of drugs like Botulinum
neurotoxin A or cell injection therapies of Mesenchymal Stromal Cells
(MSCs) or bring promising novel therapies such as Recombinant
Human Fibroblastic Growth Factor (Rh FGF-18) or Transforming
Growth Factor Beta (TGF-β) into the clinical setting through case
series evaluation [5,6]. However, it is not just rigorous study of already
establish treatments that is needed; there is also the need to identify
novel therapies. One method of doing this would be to identify an
already effective treatment in another area of musculoskeletal research,
isolate its mechanism of action and apply this to the mechanisms of
osteoarthritis. Thereby asking the question; can we teach an old drug
new tricks?
Actovegin is a drug with 50 years of clinical history; it enhances
aerobic oxidation in mammals, improving the absorption of glucose
and oxygen uptake in tissue. It has been shown in in vitro models to
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indirectly influence key players in the biochemical process of
inflammation via CD68+ and repair via CD163+ macrophages [7].
Osteoarthritic synovial cells have been shown to express elevated levels
of CD68+ markers [8]. Actovegin has been used in the treatment of
acute muscle injuries, being show to improve clinical outcomes and
reduce return to sport time in hamstring injuries of elite football
players [9]. However, the in vitro evidence outlining the mechanism of
action for Actovegin suggests it may have a role to be used in the
treatment of osteoarthritis. Possibly this could be through an intra-
articular injection. Further research here would look to review the
mechanisms of Actovegin and apply this to the relevant Osteoarthritis
evidence, possibly culminating in an experimental in vitro model. The
next step following that would be a case series to judge primarily
tolerance and safety, but at the same time to report any efficacy and
improvements in clinical outcome. This exciting area of research could
hopefully produce a realistic alternative to current therapies in a same
vain highlighted by the review on Prolotherapy.
Conclusions
Intra-articular injections are an important final line of conservative
intervention in a profession where maximising non-operative
management is highly important. The current literature does
demonstrate the need for high quality randomised controlled trialling
for definitive conclusions on efficacy of established therapies. However,
this issue of The Journal of Arthritis has highlighted the need for
pioneering case series and review articles to demonstrate initial efficacy
of promising therapies. Further, hopefully the example of Actovegin in
this editorial will inspire readers to identify potential novel therapies.
By looking to other branches of musculoskeletal injection therapy and
applying established mechanisms of action to Osteoarthritis we hope
readers will begin to ask the age old question; can you teach an old
drug new tricks?
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